MiNK Therapeutics, Inc. (INKT)

Market Cap	35.82M
Revenue (ttm)	n/a
Net Income (ttm)	-10.78M
Shares Out	3.97M
EPS (ttm)	-2.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,897
Open	9.05
Previous Close	9.23
Day's Range	9.03 - 9.11
52-Week Range	4.56 - 19.00
Beta	0.16
Analysts	Strong Buy
Price Target	37.50 (+315.28%)
Earnings Date	Mar 18, 2025

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Forecast

According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price forecast is $37.5, which is an increase of 315.28% from the latest price.

Price Target

$37.5

(315.28% upside)

Analyst Consensus: Strong Buy